Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma

Pieter Sonneveld*, Meletios A Dimopoulos, Meral Beksac, Bronno van der Holt, Sara Aquino, Heinz Ludwig, Sonja Zweegman, Thilo Zander, Elena Zamagni, Ruth Wester, Roman Hajek, Lucia Pantani, Luca Dozza, Francesca Gay, AnneMaria Cafro, Luca De Rosa, Annamaria Morelli, Henrik Gregersen, Nina Gulbrandsen, Petra CornelisseRosella Troia, Stefania Oliva, Vincent van de Velden, KaLung Wu, Paula F Ypma, Gerard Bos, Mark-David Levin, Luca Pour, Christoph Driessen, Annemiek Broijl, Alexandra Croockewit, Monique C Minnema, Anders Waage, Cecilie Hveding, Niels W C J van de Donk, Massimo Offidani, Giuseppe A Palumbo, Andrew Spencer, Mario Boccadoro, Michele Cavo

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

2 Citations (Web of Science)
Original languageEnglish
Pages (from-to)3613-3622
Number of pages10
JournalJournal of Clinical Oncology
Volume39
Issue number32
DOIs
Publication statusPublished - 10 Nov 2021

Keywords

  • Adolescent
  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols/administration & dosage
  • Bortezomib/administration & dosage
  • Consolidation Chemotherapy
  • Dexamethasone/administration & dosage
  • Europe
  • Humans
  • Lenalidomide/administration & dosage
  • Maintenance Chemotherapy
  • Middle Aged
  • Multiple Myeloma/drug therapy
  • Neoplasm Staging
  • Neoplasm, Residual
  • Progression-Free Survival
  • Time Factors
  • Young Adult
  • DEXAMETHASONE
  • CONSENSUS
  • INDUCTION
  • THERAPY
  • IMPROVES
  • STEM-CELL TRANSPLANTATION
  • OPEN-LABEL
  • BORTEZOMIB
  • OUTCOMES
  • LENALIDOMIDE MAINTENANCE

Cite this